Evidence map›Paper›PMID 39248459›Full record

ArticleJournal of virology2024

Conformations of membrane human immunodeficiency virus (HIV-1) envelope glycoproteins solubilized in Amphipol A18 lipid-nanodiscs.

Shijian Zhang, Saumya Anang, Zhiqing Zhang, Hanh T Nguyen, Haitao Ding, John C Kappes, Joseph Sodroski

Abstract read
In one paragraph

Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shijian ZhangDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID 0000-0002-2017-6754
Saumya AnangDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Zhiqing ZhangDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Hanh T NguyenDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Haitao DingDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
John C KappesDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Joseph SodroskiDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID 0000-0002-9750-1615

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
ERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0M
Understanding Envelope Function in HIV-1 Infection: The Design, Synthesis and Validation of Small Molecule HIV-1 Env InhibitorsP01AI150471 · NIAID · DREXEL UNIVERSITY · PI CHAIKEN, IRWIN M, MOTHES, WALTHER H · 2019 to 2022
$7.8M
Conformational Landscape of the HIV-1 Envelope GlycoproteinsR01AI124982 · NIAID · DANA-FARBER CANCER INST · PI SODROSKI, JOSEPH G · 2016 to 2025
$6.7M
Probing functional HIV-1 envelope glycoprotein conformations with novel potent CD4-mimetic compoundsR01AI176904 · NIAID · DANA-FARBER CANCER INST · PI WAYNE A. HENDRICKSON, WALTHER H MOTHES · 2023 to 2026
$3.4M
Combining Molecular Simulations and Biophysical Methods to Characterize Conformational Dynamics of the HIV-1 Envelope GlycoproteinR01AI178833 · NIAID · DREXEL UNIVERSITY · PI CAMERON F ABRAMS, WALTHER H MOTHES · 2023 to 2026
$3.2M
Enrichment of the State-1 Conformation of the HIV-1 Envelope GlycoproteinR01AI145547 · NIAID · DANA-FARBER CANCER INST · PI SODROSKI, JOSEPH G · 2019 to 2021
$2.2M
Reducing viral reservoirs by opening HIV-1 Env to antibody attackR33AI129017 · NIAID · DANA-FARBER CANCER INST · PI SODROSKI, JOSEPH G · 2019 to 2021
$1.6M
Reducing viral reservoirs by opening HIV-1 Env to antibody attackR21AI129017 · NIAID · DANA-FARBER CANCER INST · PI SODROSKI, JOSEPH G · 2017 to 2018
$459k
Gilead Sciences (Gilead) 02010HHS | National Institutes of Health (NIH) AI027767HHS | National Institutes of Health (NIH) AI145547,AI124982,AI150471,AI129017,AI164562,AI176904,AI178833NIAID NIH HHS P01 AI150471NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI124982NIAID NIH HHS R01 AI145547NIAID NIH HHS R01 AI176904NIAID NIH HHS R01 AI178833NIAID NIH HHS R21 AI129017NIAID NIH HHS R33 AI129017NIAID NIH HHS UM1 AI164562
6 · The paper itself

Abstract

Upon binding to the host cell receptor, CD4, the pretriggered (State-1) conformation of the human immunodeficiency virus (HIV-1) envelope glycoprotein (Env) trimer undergoes transitions to downstream conformations important for virus entry. State 1 is targeted by most broadly neutralizing antibodies (bNAbs), whereas downstream conformations elicit immunodominant, poorly neutralizing antibody (pNAb) responses. Extraction of Env from the membranes of viruses or Env-expressing cells disrupts the metastable State-1 Env conformation, even when detergent-free approaches like styrene-maleic acid lipid nanoparticles (SMALPs) are used. Here, we combine three strategies to solubilize and purify mature membrane Envs that are antigenically native (i.e., recognized by bNAbs and not pNAbs): (1) solubilization of Env with a novel amphipathic copolymer, Amphipol A18; (2) use of stabilized pretriggered Env mutants; and (3) addition of the State-1-stabilizing entry inhibitor, BMS-806. Amphipol A18 was superior to the other amphipathic copolymers tested (SMA and AASTY 11-50) for preserving a native Env conformation. A native antigenic profile of A18 Env-lipid-nanodiscs was maintained for at least 7 days at 4°C and 2 days at 37°C in the presence of BMS-806 and was also maintained for at least 1 h at 37°C in a variety of adjuvants. The damaging effects of a single cycle of freeze-thawing on the antigenic profile of the A18 Env-lipid-nanodiscs could be prevented by the addition of 10% sucrose or 10% glycerol. These results underscore the importance of the membrane environment to the maintenance of a pretriggered (State-1) Env conformation and provide strategies for the preparation of lipid-nanodiscs containing native membrane Envs.IMPORTANCEThe human immunodeficiency virus (HIV-1) envelope glycoproteins (Envs) mediate virus entry into the host cell and are targeted by neutralizing antibodies elicited by natural infection or vaccines. Detailed studies of membrane proteins like Env rely on purification procedures that maintain their natural conformation. In this study, we show that an amphipathic copolymer A18 can directly extract HIV-1 Env from a membrane without the use of detergents. A18 promotes the formation of nanodiscs that contain Env and membrane lipids. Env in A18-lipid nanodiscs largely preserves features recognized by broadly neutralizing antibodies (bNAbs) and conceals features potentially recognized by poorly neutralizing antibodies (pNAbs). Our results underscore the importance of the membrane environment to the native conformation of HIV-1 Env. Purification methods that bypass the need for detergents could be useful for future studies of HIV-1 Env structure, interaction with receptors and antibodies, and immunogenicity.

Indexed as

Antibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV-1HIV AntibodiesHumansMaleatesNanoparticlesPolymersProtein ConformationSolubilityVirus InternalizationAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesMaleatesPolymersacrylic acid-co-styrene (AASTY)adjuvantamphipathic copolymercryoprotectantnanoparticlesnative conformationneutralizing antibodypretriggered (State-1) EnvState-1 stabilizationstyrene-maleic acid (SMA)

Identifiers

PMID39248459
PMCPMC11495050

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.